A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

NCT04516278 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Wet Macular Degeneration
BRVO - Branch Retinal Vein Occlusion
Diabetic Macular Edema

Interventions

BIOLOGICAL: bevacizumab

Sponsor

Outlook Therapeutics, Inc.